On Tuesday, IDEAYA Biosciences received a positive adjustment to its Relative Strength (RS) Rating, from 69 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 in the early stages of their moves. See if IDEAYA Biosciences can continue to show renewed price strength and hit that benchmark.
IDEAYA Biosciences is now considered extended and out of buy range after clearing a 23.09 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% earnings growth in its most recent report, while sales growth came in at 79%.
IDEAYA Biosciences earns the No. 248 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
